Interestingly, thalidomide, a therapeutic agent used in severe mucocutaneous manifestations of BD, and NF-κB small interfering RNA down-regulated cFLIP and Bcl-xL expression levels, ultimately increasing activated T cells sensitivity to CD95-induced apoptosis in BD. This evidence concerns the gene BCL2L1 and Behcet disease.